FML by AbbVie is clinical pharmacology corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. Approved for corticosteroid-responsive inflammation of the palpebral, bulbar conjunctiva, cornea and 1 more indications. First approved in 1985.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
FML (fluorometholone) is a topical ophthalmic corticosteroid ointment approved in 1985 for treating inflammatory eye conditions including epiphora and ocular complications of cancer. It works by inhibiting the inflammatory cascade through induction of lipocortins, which suppress prostaglandin and leukotriene biosynthesis. The drug is a small-molecule corticosteroid with a well-established safety and efficacy profile in ophthalmology.
Mature ophthalmic product in late-stage lifecycle with modest Part D utilization; brand team focus likely transitioning to generic transition planning and line extension strategies.
CLINICAL PHARMACOLOGY Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen,…
Worked on FML at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moFML currently has no linked job openings in available datasets, reflecting its mature lifecycle and modest commercial scale ($244K Part D spending). Roles on this product are typically within regulatory affairs, medical information, or product maintenance rather than growth-focused brand or commercial teams.